Introduction
Platelets play an important role in hemostasis through adhesion and aggregation, and these functions are influenced by diseases and drugs. For example, the hyperfunction and activation of platelets have been strongly implicated in the development and recurrence of arterial occlusive disease. [1] [2] [3] [4] In the mechanisms responsible for platelet activation, it is submit your manuscript | www.dovepress.com
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Tada et al important to regulate Ca 2+ mobilization through the activation of phospholipase C 5 and the production of thromboxane A 2 (TXA 2 ), which strongly induces platelet cohesion. 6 Different substances have the ability to activate platelets in vivo, with thrombin being considered important in diseases such as thrombosis. 7, 8 On the other hand, various antiplatelet drugs are used in the treatment and prevention of these diseases. 9 New antiplatelet drugs and many other drugs have also been developed, but some of the drugs may have adverse effects on platelet functions. Therefore, the effects and adverse effects of various drugs on platelets need to be examined in more detail.
Platelet activation is regulated through intracellular Ca 2+ , which plays a pivotal role as a second messenger in the platelet aggregation mechanism. 10, 11 In order to clarify their state, it is important to evaluate changes in intracellular Ca ] i induced by thrombin have been observed in human erythroid leukemia (HEL) cells and platelets, and HEL has been shown to cause Ca 2+ mobilization induced by thrombin. 12 HEL cells are progenitor cells that have the characteristics of a megakaryocyte/platelet lineage such as platelet membrane glycoprotein IIb/IIIa, glycoprotein Ib, and TXA 2 receptor and may differentiate into megakaryocyte-like cells. HEL cells have become a useful model for the study of platelet functions, [13] [14] [15] since anyone can study platelet functions using HEL cells anytime/anywhere without sampling blood.
In the present study, attempts were made to improve the evaluation method for evaluating the effects of various drugs (aspirin and cilostazol, antiplatelet drugs; ibuprofen, an anti-inflammatory drug that has been reported to inhibit cyclooxygenase-1 [COX-1] in the same as aspirin; and sodium valproate, an anticonvulsant that has been reported to cause impairment of platelet 16 ) on platelet functions using phorbol 12-myristate 13-acetate (PMA)-induced megakaryocytic HEL cells as an alternative to platelets.
Materials and methods ethics statement
This study was approved by the ethics committee of the University of Tokushima Hospital (approval number 2072). Written informed consent was obtained from all volunteers, and all participants signed consent forms approved by the ethics committee.
chemicals
PMA was purchased from Sigma-Aldrich Co. (St Louis, MO, USA), and thrombin was from Mochida Pharmaceutical Co., Ltd. (Tokyo, Japan). Aspirin (acetylsalicylic acid) was purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan), and cilostazol was provided from Otsuka Pharmaceutical Co., Ltd. (Tokyo, Japan). Ibuprofen and sodium valproate were purchased from Sigma Chemicals (Perth, Australia). Fura2-AM was purchased from Dojindo Laboratories (Kumamoto, Japan). Dimethyl sulfoxide was purchased from Kanto Chemical Industry Co., Ltd (Tokyo, Japan). Triton X-100 was purchased from Wako Pure Chemical Industries, Ltd., acid citrate dextrose (ACD) was purchased from Terumo (Tokyo, Japan), and ethylene glycol bis(2-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA) was from Sigma-Aldrich Co.
Platelet preparation
Human blood plasma and platelets were collected from five healthy adult volunteers. Blood collected from humans was mixed with ACD (blood:ACD =6:1) and centrifuged at 200× g at room temperature for 15 minutes. Supernatant platelet-rich plasma (PRP) was incubated with Fura2-AM (3 µL Fura2-AM in 1 mL PRP) at 37°C for 50 minutes in the dark. After being incubated, ACD at 15% of total volume of PRP was added, and the mixture was centrifuged at 700× g for 10 minutes. After removal of the supernatant, the platelet pellet was washed twice with 5 mL HEPES buffer (145 mM NaCl, 5 mM KCl, 1 mM MgSO 4 , 10 mM HEPES, 5 mM glucose, and pH 7.4)/750 µL ACD (700× g for 6 minutes). The platelet count was adjusted with HEPES buffer to 2×10 8 /mL, and changes in [Ca 2+ ] i and platelet aggregation intensity were measured.
cell culture HEL cells were used as platelet model cells. 17 HEL cells were maintained in RPMI-1640 (Wako Pure Chemical Industries, Ltd.) supplemented with 10% fetal bovine serum (Biosera LTD, East Sussex, UK), 100 µg/mL penicillin G, and 100 µg/mL streptomycin at 37°C in a humidified atmosphere of 5% CO 2 . phosphate-buffered saline (PBS) twice. Adherent cells were detached form the culture bottle by treatment with 1 mM EDTA/4Na-PBS at 37°C for 10 minutes and centrifuged at 260× g at room temperature for 5 minutes. After removal of the supernatant, cell pellets were washed three times with HEPES buffer or PBS (at 260× g for 5 minutes) and then suspended in 1 mL of HEPES buffer or PBS.
Megakaryocytic differentiation of hel cells and cell processing
Flow cytometry analysis of surface cD41 expression
In order to quantify surface CD41 expression on untreated HEL cells and PMA-induced HEL cells, 100 µL of cells suspended in PBS (1×10 6 cells/mL) were incubated with 10 µL of fluorescein isothiocyanate (FITC)-conjugated anti-CD41 (Mouse Monoclonal Anti-Human CD41-FITC, Clone 5B12; DAKO Denmark A/S, Glostrup, Denmark) at 4°C for 30 minutes in the dark. A negative control was then used under the same conditions of FITC-conjugated mouse IgG isotype mAb. After the reaction had been stopped by the addition of 2,000 µL of PBS, cells were centrifuged at 260× g at room temperature for 5 minutes, and the supernatant was removed. Cells were resuspended in PBS and washed twice with PBS (at 260× g for 5 minutes). After the last wash, cells were resuspended in 500 µL of PBS and analyzed using flow cytometry (Beckman Coulter, CA, USA).
Measurement of thrombin-induced [ca
2+ ] i in hel cells and human platelets
In order to measure [Ca 2+ ] i , untreated HEL cells or PMAinduced HEL cells suspended in 1 mL of HEPES buffer were incubated with 2 µL of Fura2-AM at 37°C for 60 minutes in the dark, washed, and resuspended in the HEPES buffer at 1×10 6 cells/mL. The cell suspension in a volume of 480 µL, after a 50-second preincubation at 37°C, was treated with 10 µL of the different drugs being tested (antiplatelet drugs: aspirin and cilostazol, anti-inflammatory drug: ibuprofen, anticonvulsant drug: sodium valproate, and simultaneous combined use: aspirin and ibuprofen or sodium valproate) for 6 minutes. The suspended cells were stimulated with 20 µL of thrombin at 0.8-1.0 U/mL for 100 seconds, resulting in [Ca 2+ ] i of ~200 nM, after which 100 µL of 1% Triton X-100, and then 100 µL of 100 mM EGTA were added. Fluorescence was measured at excitation wavelengths of 340 nm and 380 nm and an emission wavelength of 510 nm, and platelet aggregation was measured by light scattering after 3 minutes at an excitation wavelength of 380 nm and an emission wavelength of 400 nm using a fluorescence spectrophotometer (F-2500; Hitachi Ltd., Tokyo, Japan). ] i in human platelet and platelet aggregation intensity following stimulation with thrombin (0.01-0.08 U/ml). results are expressed as the mean ± standard deviation of five subjects. The 
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Tada et al observed in microscopic and flow cytometric analyses; most of the small cells became larger megakaryocyte-like cells with positive multinuclear and periodic acid-Schiff staining. These cells adhered strongly to the bottom of the culture bottle ( Figure 2B ). Furthermore, untreated HEL cells were mainly a small cell population of gate I ( Figure 2C ). On the other hand, PMA-induced HEL cells were divided into three gates based on size by cell flow cytometry ( Figure 2D ). The expression of the surface CD41 antigen, a platelet marker, in each group was confirmed. The expression of the surface CD41 antigen was stronger on PMA-induced HEL cells than that on untreated HEL cells. Its strong expression was observed on large cells in gate II (Table 1) .
effects of antiplatelet agents on [ca
2+
] i induced by thrombin in untreated hel cells or PMa-induced hel cells ] i were significantly inhibited in PMAinduced HEL cells at all concentrations tested ( Figure 3A) . On the other hand, cilostazol at 1-10 µM also caused the ] i in both HEL cell types, and this inhibition was stronger in PMAinduced HEL cells than in untreated HEL cells ( Figure 3B ). The combination experiment using PMA-induced HEL cells was carried out, since the effects and adverse effects of drugs could be widely evaluated by using PMA-induced HEL cells. Figure 5 shows the interaction effects of the simultaneous combined use of aspirin and ibuprofen or sodium valproate in PMA-induced HEL cells. As shown in Figure 5A , the simultaneous combination of 0.8 µM or 8 µM ibuprofen significantly reduced the inhibitory effects of aspirin on [Ca 2+ ] i increases induced by thrombin, whereas the inhibitory effects of the simultaneous combination of 80 µM or 200 µM ibuprofen were significantly suppressed ( Figure 5B ). On the other hand, 50 µg/mL and 100 µg/mL of sodium valproate significantly increased the inhibitory effects of aspirin on [Ca 2+ ] i increases induced by thrombin ( Figure 5C ).
Discussion
The activation and hyperfunction of platelets have recently been strongly implicated in the development and recurrence of arterial occlusive diseases, and various antiplatelet drugs are used in the treatment and prevention of these diseases, and new antiplatelet drugs and many other drugs have been developed. Therefore, the evaluation of platelet functions is of importance, particularly the effects and adverse effects of various drugs. ] i induced by thrombin. Notes: Fura2-loaded PMa-induced hel cells were treated with the simultaneous combined use of aspirin (asa) and ibuprofen (iBU) (A and B) or sodium valproate (VPa) (C) for 6 minutes, then stimulated with thrombin. intracellular ca 2+ mobilization was induced by thrombin. results are presented as the mean ± sD, n=5. **P,0.01 and *P,0.05 (student's t-test Platelet functions are currently assessed based on platelet aggregation with light transmission aggregometry. This is one of the methods used to measure platelet functions and has been routinely used to measure platelet aggregation activity, but such platelet aggregation is merely a secondary reaction. Platelets are activated by some factors, with thrombin being of importance, and previous studies have detected activated platelets in the blood of patients with progressive arterial thrombosis. 7, 8 Platelet aggregation is induced by intracellular Ca Aspirin and cilostazol were selected as antiplatelet drugs, and ibuprofen and sodium valproate have been reported to have adverse effects on platelet functions. Aspirin causes the irreversible inactivation of cyclooxygenase activity by acetylating Ser-530 (also referred to as Ser-529) of COX-1, thereby inhibiting TXA 2 production and suppressing platelet function through the inhibition of [Ca 2+ ] i in platelets. [19] [20] [21] On the other hand, cilostazol is a cyclic AMP (cAMP) phosphodiesterase III inhibitor, inhibiting phosphodiesterase activity and suppressing [Ca 2+ ] i by inhibiting cAMP in platelets. [22] [23] [24] [25] Although the mechanisms of action of aspirin and cilostazol differ, these drugs control platelet function by inhibiting [Ca 2+ ] i in platelets. In the present study, aspirin (5.6-560 µM) inhibited thrombin-induced increases in [Ca 2+ ] i in a concentration-dependent manner in untreated HEL cells and PMA-induced HEL cells. Thrombin-induced increases in [Ca 2+ ] i in PMA-induced HEL cells were significantly inhibited by all concentrations of aspirin. Cilostazol (1-10 µM) also inhibited thrombin-induced increases in [Ca 2+ ] i in a concentration-dependent manner in untreated HEL cells and PMA-induced HEL cells, with these increases being significantly inhibited by 10 µM or 5 µM and 10 µM cilostazol, respectively. On the other hand, ibuprofen is an anti-inflammatory drug that inhibits COX-1 in the same as aspirin, but the action sites of aspirin and ibuprofen are different. Ibuprofen inhibits COX-1 reversibly by forming a salt bridge with Arg-120 26 and also inhibits the generation of TXA 2 , which is a platelet aggregation promoter. 27 32 also reported reactions on platelet aggregation with the combination of aspirin and ibuprofen. Thus, it was attempted to evaluate the effects of interaction in thrombin-induced increases in [Ca 2+ ] i in combination with aspirin and ibuprofen. In this study, high-dose aspirin (56 µM) was selected in order to clarify the interaction of ibuprofen. In combination with aspirin and ibuprofen, when the inhibitory effect of aspirin is higher than that of ibuprofen, the effect of aspirin was reduced, whereas when the inhibitory effect of aspirin is lower than that of ibuprofen, the effect of ibuprofen was reduced. The quantitative relationship between aspirin and ibuprofen has not yet been elucidated in detail. On the other hand, low-dose aspirin (5.6 µM) was selected in combination of sodium valproate. The combination of aspirin and sodium valproate synergistically inhibited thrombin-induced [Ca 2+ ] i . The increase in this inhibition rate is considered to occur because the action sites of aspirin and sodium valproate are different. Gidal 34 also reported the lower activity of the AA cascade and decreased production of TXA 2 in the platelets of patients receiving sodium valproate therapy. These findings suggest that sodium valproate inhibits the production of TXA 2 in the AA cascade. However, the mechanism of action of sodium valproate on the platelet AA cascade has not yet been elucidated in detail. Furthermore, to the best of our knowledge, the mechanism of action of sodium valproate on intracellular Ca 2+ in platelets currently remains unclear; therefore, further studies are warranted.
Conclusion
The results of the present study indicate that the effects and adverse effects of drug combinations may be evaluated based on the inhibition of increases in [Ca 2+ ] i induced by thrombin in PMA-induced HEL cells. In conclusion, it is possible to induce HEL cells to differentiate into megakaryocytes, which are a useful model for the study of platelet functions, and the quantification of inhibitory effects on thrombin-induced increases in [Ca 2+ ] i is applicable to the evaluation of the effects of various drugs on platelets. Furthermore, this system of evaluation using these platelet model cells may contribute to the selection of appropriate drugs and doses for the control of platelet functions without using platelets, and its use is expected in the future in this field.
